FOXO4-DRI is a retro-inverso peptide derived from FOXO4, a transcription factor belonging to the Forkhead family. The DRI (D-retro-inverso) designation refers to its construction using D-amino acids assembled in reverse sequence, which confers significant resistance to proteolytic degradation while maintaining structural mimicry of the native peptide. It was designed to interfere with the interaction between FOXO4 and p53 within the nucleus of senescent cells.
Researchers have studied FOXO4-DRI as a potential senolytic research tool – a compound that may selectively induce apoptosis in senescent cells while sparing healthy, non-senescent cells. The proposed mechanism involves competitive disruption of the FOXO4-p53 interaction, which in senescent cells is thought to suppress p53-driven apoptosis and promote their survival. Research has examined whether disrupting this interaction releases p53 to activate apoptotic pathways selectively in these cells.
Preclinical research in mouse models of induced senescence has examined FOXO4-DRI’s effects on markers of senescent cell burden, physical fitness parameters, and fur density in aged animals. Researchers have explored its potential to reduce the senescence-associated secretory phenotype (SASP), a collection of pro-inflammatory factors released by senescent cells. Its selective mechanism makes it a valuable research tool in the growing field of senescence biology.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
